Yoshimura H, Nariai Y, Terashima M, Mitani T, Tanigawa Y
Upload the lab results as a PDF through the platform's patient portal
In this trial, 17,604 patients were enrolled to receive semaglutide 2.4 mg weekly or placebo and followed for approximately 36 months
DPP-4 inhibition via gemigliptin prevents the abnormal vascular remodeling induced by oxidative stress via the activation of nuclear factor erythroid-derived 2 (NF-E2)-related factor 2 (57)
Clinical data shows that GLP-1 therapy effectiveness relies on steady-state dosingyour body adapts to consistent weekly exposure
Comparing GLP-1 Therapies With Metformin and SGLT2 Inhibitors When placing GLP-1 therapies within the broader treatment algorithm, its important to compare them with other commonly used drugs